Evolus, Inc. (EOLS) stock
EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.07+0.38 (+5.68%)
Close on Nov 18, 2026Market cap $466.98MP/E –Yield –
Evolus net income
Net income is the profit left for shareholders after every expense, interest and tax.
Evolus's net income for the twelve months ending Jun 30, 2026 was -$34.33M. For fiscal 2025 it was -$51.64M. The highest annual figure on record is -$4.48M in fiscal 2017.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$51.64M | – |
| FY2024 | Dec 31, 2024 | -$50.42M | – |
| FY2023 | Dec 31, 2023 | -$61.69M | – |
| FY2022 | Dec 31, 2022 | -$74.41M | – |
| FY2021 | Dec 31, 2021 | -$46.81M | – |
| FY2020 | Dec 31, 2020 | -$163.01M | – |
| FY2019 | Dec 31, 2019 | -$90.03M | – |
| FY2018 | Dec 31, 2018 | -$46.87M | – |
| FY2017 | Dec 31, 2017 | -$4.48M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$8.05M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.67M | – |
| Q4 FY2025 | Dec 31, 2025 | $130.00K | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.74M | – |
| Q2 FY2025 | Jun 30, 2025 | -$17.14M | – |
| Q1 FY2025 | Mar 31, 2025 | -$18.89M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.79M | – |
| Q3 FY2024 | Sep 30, 2024 | -$19.17M | – |
| Q2 FY2024 | Jun 30, 2024 | -$11.35M | – |
| Q1 FY2024 | Mar 31, 2024 | -$13.11M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.83M | – |
| Q3 FY2023 | Sep 30, 2023 | -$16.92M | – |
| Q2 FY2023 | Jun 30, 2023 | -$18.14M | – |
| Q1 FY2023 | Mar 31, 2023 | -$14.79M | – |
| Q4 FY2022 | Dec 31, 2022 | -$13.16M | – |
| Q3 FY2022 | Sep 30, 2022 | -$20.28M | – |
| Q2 FY2022 | Jun 30, 2022 | -$23.47M | – |
| Q1 FY2022 | Mar 31, 2022 | -$17.50M | -373.4% |
| Q4 FY2021 | Dec 31, 2021 | -$18.18M | – |
| Q3 FY2021 | Sep 30, 2021 | -$19.43M | – |
| Q2 FY2021 | Jun 30, 2021 | -$15.60M | – |
| Q1 FY2021 | Mar 31, 2021 | $6.40M | – |
| Q4 FY2020 | Dec 31, 2020 | -$110.69M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.46M | – |
| Q2 FY2020 | Jun 30, 2020 | -$21.13M | – |
| Q1 FY2020 | Mar 31, 2020 | -$19.74M | – |
| Q4 FY2019 | Dec 31, 2019 | -$14.51M | – |
| Q3 FY2019 | Sep 30, 2019 | -$26.98M | – |
| Q2 FY2019 | Jun 30, 2019 | -$37.57M | – |
| Q1 FY2019 | Mar 31, 2019 | -$10.98M | – |
| Q4 FY2018 | Dec 31, 2018 | -$12.44M | -379.7% |
| Q3 FY2018 | Sep 30, 2018 | -$11.83M | – |
| Q2 FY2018 | Jun 30, 2018 | -$16.43M | – |
| Q1 FY2018 | Mar 31, 2018 | -$6.16M | – |
| Q4 FY2017 | Dec 31, 2017 | $4.45M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.63M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.30M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.00M | – |
See a number that looks wrong?